CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker delivered when needed to treat often highly symptomatic and unpredictable episodes of PSVT. With CARDAMYST, adults with PSVT ...
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...
Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has given ...
The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...
The US FDA has approved etripamil (Cardamyst) nasal spray for the self-administered treatment of acute symptomatic paroxysmal supraventricular tachycardia (PSVT) in adults. This approval, ...
MONTREAL/CHARLOTTE - The U.S. Food and Drug Administration has approved CARDAMYST (etripamil) nasal spray for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia ...
Obstructive sleep apnea and atrial fibrillation (AFib) are two conditions that share a potentially deadly link. Having one increases the odds of developing the other, and together, the breathing ...
Investing.com -- Milestone Pharmaceuticals (NASDAQ:MIST) stock surged 35% after the company received FDA approval for CARDAMYST, the first self-administered nasal spray for adults with paroxysmal ...
Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with AFib.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback